Cash Flow Statement

Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mangoceuticals (MGRX) Preferred Shares Issued (2024 - 2025)

Mangoceuticals' Preferred Shares Issued history spans 2 years, with the latest figure at -$1.0 million for Q2 2025.

On a quarterly basis, Preferred Shares Issued changed N/A to -$1.0 million in Q2 2025 year-over-year; TTM through Dec 2025 was $100000.0, a N/A change, with the full-year FY2025 number at $100000.0, down 96.23% from a year prior.
Preferred Shares Issued hit -$1.0 million in Q2 2025 for Mangoceuticals, down from $1.2 million in the prior quarter.
Over the last five years, Preferred Shares Issued for MGRX hit a ceiling of $1.2 million in Q1 2025 and a floor of -$1.0 million in Q2 2025.